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antidepressant medication adherence. The improvements seen 
in the antidepressant medication adherence improvement initia-
tives can be attributed to the strength of the interventional
program. Although results of our study are encouraging,
expanded effort is needed to further improve the persistence rate
at 180 days.
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OBJECTIVES: Assess the relative performance of new antide-
pressants in terms of compliance, drug switching and cost.
METHODS: A total of 246,116 episodes of antidepressant
therapy were abstracted from the fee-for-service paid claims ﬁle
of the California Medicaid (Medi-Cal) program for year
1999–2002. Episodes of treatment using sertraline, paraxetine,
ﬂuoxetine, citalopram, bupropion or venlafaxine were selected
for study. Data for each episode cover six-months prior and 12
months post-treatment. RESULTS: Most episodes of antidepres-
sant therapy are for patients who restarted therapy using 
the same medication (53.2%) or on a second antidepressant
(18.9%), followed by augmentation episodes (14.8%) and
switching episodes with no break in treatment (13.6%). Antide-
pressants open formulary access (paraxetine and ﬂuoxetine) are
more frequently used in restarting episodes using the same 
medication. Patients who restart therapy display better adher-
ence and lower switching rates than patients who switch or
augment therapy, thus biasing upward the overall treatment
compliance performance of open-access antidepressants. Unad-
justed data for restart and delay switching episodes suggest that
patients treated with sertraline and venlafaxine achieve longer
duration of therapy than patients treated other drugs with other
drugs. Differences are relatively minor across all of the antide-
pressants studied with the exception of bupropion. CONCLU-
SIONS: Unadjusted results indicate little difference in patient
outcomes across alternative antidepressants. However, physi-
cians may be selectively prescribing drugs to those sub-
populations where each drug may have a clinical advantage. For
future research, propensity scoring methods will be used to inves-
tigate if clinicians have been successful in prescribing alternative
medications for those sub-populations in which each product
achieves superior outcomes.
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OBJECTIVES: Retrospective claims were assessed to determine
factors associated with meeting National Committee for Quality
Assurance (NCQA) guidelines for Antidepressant Medication
Management and impact of NCQA compliance on expenditures.
METHODS: Using MarketScan Commercial Claims and
Encounter database, adult patients with depression and initiat-
ing on tricyclics (TCAs), selective serotonin reuptake inhibitors
(SSRIs), venlafaxine (SNRI), and “other” (bupropion, nefa-
zodone, or mirtazapine) were followed for 12-months (2001-
Q12003). Claimants with schizophrenia, bipolar, psychoses, or
prior antidepressants were excluded. Factors associated with
compliance (demographics, comorbidities, initiating antidepres-
sants) were assessed in the sample (n = 48,098) using logistic
regression. Exponential conditional mean models were used to
determine the marginal effect of compliance on expenditures.
RESULTS: In total, 29% of patients had optimal provider visits
during the 12-week acute treatment phase. These patients were
more likely to initiate therapy on SNRIs and “other antidepres-
sants” (all p < 0.001). Patients with capitated insurance cover-
age, initiating on TCAs, not seen by mental health specialists or
residing in the South were less likely to be compliant (all p <
0.001). Sixty-eight percent and 49% met minimum NCQA
guidelines during acute and six-month continuation treatment
phases, respectively. Males, those younger in age, having comor-
bid conditions, not seen by non-mental health specialists or resid-
ing in the South were less likely to be compliant in either
treatment phase (all p < 0.001). Compared to SSRIs, users of
“other antidepressants” were less likely to be compliant and
SNRI users were more likely to be compliant in acute and con-
tinuation phases; initiators on TCAs were more likely to be 
compliant in the continuation phase (all p < 0.001). NCQA com-
pliant patients incurred an additional $1430 expenditures per
year compared to non-compliant patients. CONCLUSIONS:
Compliance with NCQA guidelines was less than optimal and
associated with initiating drug type, comorbidities, gender, age,
and geographic region. Improved management of these patients
could result in reduced illness burden.
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OBJECTIVES: Antidepressant medications are frequently used
for the treatment of various psychiatric disorders, including
depressive and anxiety disorders. Expenditure for antidepres-
sants in 2001 was ranked as number one among all therapeutic
categories in US. The objectives of this study were to examine
antidepressant utilization trends and to understand market-
share competition between brand-name and generic drugs.
METHODS: Three major classes of antidepressants are selective
serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants
(TCAs), and other antidepressants. Using the Center for Medic-
aid/Medicare Services (CMS) prescription drug database, we
constructed quarterly per-prescription reimbursement ﬁgures for
each brand-name and generic drug from 1991 to 2004. The
market-share for each drug or class was calculated as the 
proportion of total number of antidepressant prescriptions.
RESULTS: Total expenditure of antidepressants increased
sharply from $18 million per quarter in 1991 to $350 million
per quarter from 2001–2004. The proportion of total expendi-
ture for brand-name drugs increased from 70% in 1991 to 94%
in 2001. Brand-name market-share increased dramatically from
27% in 1991 to 50% in the second quarter of 1997, and then
to 63% in the ﬁrst quarter of 2001. In the third quarter of 2001,
brand-name market-share dropped to 52%. SSRIs (Prozac®,
Zoloft®, Luvox®, Paxil®) dominated the brand-name market.
The market share for Prozac® decreased sharply from 23% in
the third quarter of 2000 to 2% in the ﬁrst quarter of 2004, due
to its generic entry. Celexa’s® market share decreased from 20%
in the third quarter of 2002 to 15% in the ﬁrst quarter of 2004,
due to the market entry of Lexapro®. Generic antidepressant
market-shares decreased over time, particularly those of TCAs.
CONCLUSION: Large increases in antidepressant drug expen-
ditures paralleled increases in brand-name market-share. Com-
